Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 6/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1561627 | 1.00 | LPAR1 (0.67) | LPAR1HDAC1SMPD1HDAC8HDAC6 | |
| SCHEMBL26242667 | 0.94 | LPAR1 (0.64) | LPAR1HDAC1SMPD1HDAC8HDAC6 | |
| SCHEMBL26242451 | 0.94 | LPAR1 (0.64) | LPAR1HDAC1SMPD1HDAC8HDAC6 | |
| SCHEMBL1561405 | 0.93 | LPAR1 (0.67) | LPAR1HDAC1SMPD1HDAC8HDAC6 | |
| Fipaxalparant SCHEMBL1560214 | 0.93 | LPAR1 (0.78) | LPAR1HDAC1SMPD1HDAC8HDAC6 | |
| Fipaxalparant SCHEMBL29382253 | 0.93 | LPAR1 (0.78) | LPAR1HDAC1SMPD1HDAC8HDAC6 | |
| Fipaxalparant SCHEMBL29398637 | 0.93 | LPAR1 (0.78) | LPAR1HDAC1SMPD1HDAC8HDAC6 | |
| SCHEMBL1561533 | 0.92 | LPAR1 (0.67) | LPAR1HDAC1SMPD1HDAC8HDAC6 | |
| Fipaxalparant SCHEMBL25385993 | 0.91 | LPAR1 (0.65) | LPAR1HDAC1SMPD1HDAC8HDAC6 | |
| SCHEMBL4222727 | 0.91 | LPAR1 (0.57) | LPAR1HDAC1SMPD1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4486719-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | Horizon Therapeutics Ireland DAC (IE) | 2025-01-08 | — | — | EP | claimed |
| WO-2023166346-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-09-07 | — | — | WO | claimed |
| EP-4486719-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | Horizon Therapeutics Ireland DAC (IE) | 2025-01-08 | — | — | EP | disclosed |
| EP-4486328-A1 | TREATMENT OF SYSTEMIC SCLEROSIS AND IDIOPATHIC PULMONARY FIBROSIS | Horizon Therapeutics Ireland DAC (IE) | 2025-01-08 | — | — | EP | disclosed |
| US-20230414547-A1 | METHODS OF TREATING SYSTEMIC SCLEROSIS AND IDIOPATHIC PULMONARY FIBROSIS | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-12-28 | — | — | US | disclosed |
| WO-2023166346-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166348-A1 | TREATMENT OF SYSTEMIC SCLEROSIS AND IDIOPATHIC PULMONARY FIBROSIS | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-09-07 | — | — | WO | disclosed |
| EP-4204392-A2 | CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKING | Sanofi (FR) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022043755-A2 | CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKING | SANOFI (FR) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414547-A1 | METHODS OF TREATING SYSTEMIC SCLEROSIS AND IDIOPATHIC PULMONARY FIBROSIS | LPAR2, LPAR1, LPAR3 | LPAR1 2/4885HDAC1 484/4885SMPD1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.